Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vijay Benade

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
European Journal of Medicinal Chemistry|September 13, 2015
Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's diseaseRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
International Journal of Geriatric Psychiatry|September 28, 2022
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analysesRamakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, et al.
European Journal of Pharmacology|March 30, 2023
Usmarapride (SUVN-D4010), a 5-HT<sub>4</sub> receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profilingRamakrishna Nirogi, Venkata Ramalingayya Grandhi, Rajeshbabu Medapati, et al.
Journal of Medicinal Chemistry|May 16, 2018
Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT<sub>4</sub> Receptor Partial AgonistsRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Sleep Medicine|November 6, 2024
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsyRamakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, et al.
Journal of Medicinal Chemistry|February 18, 2017
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT<sub>6</sub>) Receptor Antagonist for Potential Treatment of Alzheimer's DiseaseRamakrishna Nirogi, Anil Shinde, Rama Sastry Kambhampati, et al.
Journal of Medicinal Chemistry|January 11, 2019
Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H<sub>3</sub> Receptor Inverse Agonist with Robust Wake-Promoting ActivityRamakrishna Nirogi, Anil Shinde, Abdul Rasheed Mohammed, et al.
Chemmedchem|November 11, 2021
1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H<sub>3</sub> Receptor Inverse Agonist with Efficacy in Animal Models of CognitionAnil Karbhari Shinde, Rajesh Kumar Badange, Veena Reballi, et al.
Journal of Medicinal Chemistry|July 12, 2021
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT<sub>4</sub> Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's DiseaseRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Journal of Medicinal Chemistry|September 13, 2015
Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's diseaseRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
International Journal of Geriatric Psychiatry|September 28, 2022
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analysesRamakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, et al.
European Journal of Pharmacology|March 30, 2023
Usmarapride (SUVN-D4010), a 5-HT<sub>4</sub> receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profilingRamakrishna Nirogi, Venkata Ramalingayya Grandhi, Rajeshbabu Medapati, et al.
Journal of Medicinal Chemistry|May 16, 2018
Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT<sub>4</sub> Receptor Partial AgonistsRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Sleep Medicine|November 6, 2024
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsyRamakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, et al.
Journal of Medicinal Chemistry|February 18, 2017
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT<sub>6</sub>) Receptor Antagonist for Potential Treatment of Alzheimer's DiseaseRamakrishna Nirogi, Anil Shinde, Rama Sastry Kambhampati, et al.
Journal of Medicinal Chemistry|January 11, 2019
Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H<sub>3</sub> Receptor Inverse Agonist with Robust Wake-Promoting ActivityRamakrishna Nirogi, Anil Shinde, Abdul Rasheed Mohammed, et al.
Chemmedchem|November 11, 2021
1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H<sub>3</sub> Receptor Inverse Agonist with Efficacy in Animal Models of CognitionAnil Karbhari Shinde, Rajesh Kumar Badange, Veena Reballi, et al.
Journal of Medicinal Chemistry|July 12, 2021
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT<sub>4</sub> Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's DiseaseRamakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, et al.
Pageof 3